Abstract
We previously demonstrated that the intraperitoneal administration of palmitoylethanolamide (PEA) in mice with chronic constriction injury of the sciatic nerve evoked a relief of both thermal hyperalgesia and mechanical allodynia in neuropathic mice. Since diabetic neuropathy is one of the most common long-term complications of diabetes, we explored the ability of PEA to also relief this kind of chronic pain, employing the well established streptozotocin-induced animal model of type 1 diabetes. Our findings demonstrated that PEA relieves mechanical allodynia, counteracts nerve growth factor deficit, improves insulin level, preserves Langherans islet morphology reducing the development of insulitis in diabetic mice. These results suggest that PEA could be effective in type1 -diabetic patients not only as pain reliever but also in controlling the development of pathology.
Keywords: Allodynia, diabetes, endocannabinoid, insulin, insulitis, mast cell, nerve growth factor, neuropathy, oxidative stress, Palmitoylethanolamide.
CNS & Neurological Disorders - Drug Targets
Title:Palmitoylethanolamide Relieves Pain and Preserves Pancreatic Islet Cells in a Murine Model of Diabetes
Volume: 14 Issue: 4
Author(s): Giulia Donvito, Isabella Bettoni, Francesca Comelli, Anita Colombo and Barbara Costa
Affiliation:
Keywords: Allodynia, diabetes, endocannabinoid, insulin, insulitis, mast cell, nerve growth factor, neuropathy, oxidative stress, Palmitoylethanolamide.
Abstract: We previously demonstrated that the intraperitoneal administration of palmitoylethanolamide (PEA) in mice with chronic constriction injury of the sciatic nerve evoked a relief of both thermal hyperalgesia and mechanical allodynia in neuropathic mice. Since diabetic neuropathy is one of the most common long-term complications of diabetes, we explored the ability of PEA to also relief this kind of chronic pain, employing the well established streptozotocin-induced animal model of type 1 diabetes. Our findings demonstrated that PEA relieves mechanical allodynia, counteracts nerve growth factor deficit, improves insulin level, preserves Langherans islet morphology reducing the development of insulitis in diabetic mice. These results suggest that PEA could be effective in type1 -diabetic patients not only as pain reliever but also in controlling the development of pathology.
Export Options
About this article
Cite this article as:
Donvito Giulia, Bettoni Isabella, Comelli Francesca, Colombo Anita and Costa Barbara, Palmitoylethanolamide Relieves Pain and Preserves Pancreatic Islet Cells in a Murine Model of Diabetes, CNS & Neurological Disorders - Drug Targets 2015; 14 (4) . https://dx.doi.org/10.2174/1871527314666150429111537
DOI https://dx.doi.org/10.2174/1871527314666150429111537 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design Metabolic Therapy of Heart Failure
Current Pharmaceutical Design Mitochondrial Disorders in Adults
Current Molecular Medicine Diabetes and the Impairment of Reproductive Function: Possible Role of Mitochondria and Reactive Oxygen Species
Current Diabetes Reviews Differential Susceptibility of Naive and Differentiated PC-12 Cells to Methylglyoxal-Induced Apoptosis: Influence of Cellular Redox
Current Neurovascular Research Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking
Current Genomics Foot Injuries Among Hajj Pilgrims with and Without Diabetes Mellitus: Implications for Infection Management
Infectious Disorders - Drug Targets Sexual Dimorphism in Autoimmune Disease
Current Molecular Medicine Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Approaches for the Cure of Type 1 Diabetes by Cellular and Gene Therapy
Current Gene Therapy Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design T9-T10 Osteomyelitis, Epidural Abscess and Cord Compression Secondary to <i>Mycobacterium abscessus</i>: A Case Report
Infectious Disorders - Drug Targets Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews Mitochondrial Dysfunction, Oxidative Stress and Diabetic Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease
Current Pharmaceutical Design Human Umbilical Cord Blood as an Emerging Stem Cell Therapy for Diabetes Mellitus
Current Stem Cell Research & Therapy Anti-Proliferative, Anti-Inflammatory, Anti-Ulcerogenic and Wound Healing Properties of Chitosan
Current Bioactive Compounds